23:04 , Feb 22, 2018 |  BC Innovations  |  Targets & Mechanisms

Molecular mentality

A Science study of gene expression signatures in psychiatric disease patients is the field’s largest transcriptomic readout to date, moving it closer toward molecular characterization of mental disorders. By helping map targets and pathways, the...
23:38 , Oct 24, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A biobank of insertional mutagenesis-derived haploid mouse ESCs could be used to link genes to disease-related phenotypes in homogeneous cell populations. The biobank consists of over 100,000 haploid mouse ESCs with genetically...
03:49 , Sep 28, 2017 |  BC Extra  |  Preclinical News

Researchers report first Haplobank data

In a paper published in Nature , researchers at the Austrian Academy of Sciences and colleagues reported the first data from Haplobank, an open-access haploid mouse embryonic stem cell (ESC) bank created in collaboration with...
18:34 , Jul 6, 2017 |  BC Week In Review  |  Company News

CSPC's AlaMab gets rights to UT Health San Antonio's mAbs

The University of Texas' UT Health San Antonio granted the AlaMab Therapeutics Inc. subsidiary of CSPC Pharmaceutical Group Ltd. (HKSE:1093; Pink:CHPTY) exclusive, worldwide rights to IP covering two protein channel mAbs. AlaMab's license covers the...
21:18 , Jun 27, 2017 |  BC Extra  |  Company News

CSPC's AlaMab gets rights to UT Health San Antonio's mAbs

The University of Texas ' UT Health San Antonio granted the AlaMab Therapeutics Inc. subsidiary of CSPC Pharmaceutical Group Ltd. (HKSE:1093; Pink:CHPTY) exclusive, worldwide rights to IP covering two protein channel mAbs. AlaMab's license covers...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

FirstString Research, Relief Therapeutics deal

Relief will acquire dermatology company FirstString in a stock deal. FirstString’s Granexin Gel , a bioengineered peptide gel mimetic of the carboxyl-terminus of gap junction protein alpha 1, 43kDa (GJA1; X43; connexin-43 ), is slated...
07:00 , Jun 16, 2016 |  BC Innovations  |  Translation in Brief

Dysfunction junction

Researchers from Memorial Sloan Kettering Cancer Center have shown brain metastases build gap junctions to flood neighboring astrocytes with pro-inflammatory signaling molecules, causing the cells to secrete cytokines that fuel tumor growth via a paracrine...
07:00 , Jun 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Gap junction protein α 1, 43kDa (GJA1; CX43; connexin-43); protocadherin 7 (PCDH7)

Cancer INDICATION: Breast cancer; non-small cell lung cancer (NSCLC); cancer Patient sample and mouse studies suggest inhibiting GJA1 or PCDH7 could help treat brain metastases of breast cancer, NSCLC and other solid tumor types. In...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Gap junction protein α 1, 43kDa (GJA1; CX43; connexin-43)

Cancer INDICATION: Brain cancer Cell culture, mouse and patient sample studies suggest GJA1 inhibitors could help treat temozolomide-resistant glioblastoma. In human glioblastoma cell lines and patient-derived glioblastoma cells, high levels of GJA1 expression correlated with...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

ACT 1: Phase II data

An Indian Phase II trial in patients with chronic venous leg ulcers showed that topical Granexin gel plus standard of care (SOC) significantly reduced mean percent ulcer area from baseline to week 12 by 79%...